JP2005516073A - ＩＩβ型ホスホイノシチドリン酸キナーゼの調節 - Google Patents

ＩＩβ型ホスホイノシチドリン酸キナーゼの調節 Download PDF

Info

Publication number
JP2005516073A
JP2005516073A JP2003564071A JP2003564071A JP2005516073A JP 2005516073 A JP2005516073 A JP 2005516073A JP 2003564071 A JP2003564071 A JP 2003564071A JP 2003564071 A JP2003564071 A JP 2003564071A JP 2005516073 A JP2005516073 A JP 2005516073A
Authority
JP
Japan
Prior art keywords
pipkiiβ
polypeptide
subject
nucleic acid
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003564071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516073A5 (enExample
Inventor
カントレー，ルイス，シー．
ラミア，カッジャ，エイ．
ラメ，ルシア
カーン，バーバラ
ペローニ，オディール
Original Assignee
ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド filed Critical ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド
Publication of JP2005516073A publication Critical patent/JP2005516073A/ja
Publication of JP2005516073A5 publication Critical patent/JP2005516073A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Environmental Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
JP2003564071A 2002-02-01 2003-02-03 ＩＩβ型ホスホイノシチドリン酸キナーゼの調節 Pending JP2005516073A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35375802P 2002-02-01 2002-02-01
PCT/US2003/003065 WO2003064451A2 (en) 2002-02-01 2003-02-03 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE

Publications (2)

Publication Number Publication Date
JP2005516073A true JP2005516073A (ja) 2005-06-02
JP2005516073A5 JP2005516073A5 (enExample) 2006-03-23

Family

ID=27663251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564071A Pending JP2005516073A (ja) 2002-02-01 2003-02-03 ＩＩβ型ホスホイノシチドリン酸キナーゼの調節

Country Status (5)

Country Link
US (1) US20060089320A1 (enExample)
EP (1) EP1481093A4 (enExample)
JP (1) JP2005516073A (enExample)
CA (1) CA2473990A1 (enExample)
WO (1) WO2003064451A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012112245A1 (en) * 2011-02-14 2012-08-23 Beth Israel Deaconess Medical Center, Inc. Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291172B1 (en) * 1995-03-03 2001-09-18 Mitokor Diagnostic assay for diabetes mellitus based on mutational burden
AU712607B2 (en) * 1996-02-02 1999-11-11 Merck & Co., Inc. Method of treating diabetes and related disease states
AU4724099A (en) * 1998-06-26 2000-01-17 University Of Utah Research Foundation Immobilized reagents for kinase assays
CN1321756A (zh) * 2000-04-29 2001-11-14 上海博德基因开发有限公司 一种新的多肽——人磷脂酰肌－4－磷酸－5－激酶Ⅱbeta亚基13和编码这种多肽的多核苷酸
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6009013919, ＲＡＭＥＨ，Ｌ．Ｅ． ｅｔ ａｌ, "Ａ ｎｅｗ ｐａｔｈｗａｙ ｆｏｒ ｓｙｎｔｈｅｓｉｓ ｏｆ ｐｈｏｓｐｈａｔｉｄｙｌｉｎｏｓｉｔｏｌ−４，５−ｂｉｓｐｈｏｓｐｈａｔｅ", Ｎａｔｕｒｅ, 1997, Ｖｏｌ．３９０， Ｎｏ．６６５６, ｐ．１９２−６ *
JPN6009061223, ＣＡＳＴＥＬＬＩＮＯ，Ａ．Ｍ． ｅｔ ａｌ, "Ａ ｎｏｖｅｌ ｉｎｔｅｒａｃｔｉｏｎ ｂｅｔｗｅｅｎ ｔｈｅ ｊｕｘｔａｍｅｍｂｒａｎｅ ｒｅｇｉｏｎ ｏｆ ｔｈｅ ｐ５５ ｔｕｍｏｒ ｎｅｃｒｏｓｉｓ ｆａｃｔｏｒ ｒｅｃｅｐｔｏｒ ａｎｄ ｐ", Ｊ Ｂｉｏｌ Ｃｈｅｍ, 1997, Ｖｏｌ．２７２， Ｎｏ．９, ｐ．５８６１−７０ *
JPN7009001570, ＭＯＲＩＮ，Ｌ． ｅｔ ａｌ, "Ｄｅｃｒｅａｓｅｄ ＡＴＰ−ｉｎｄｕｃｅｄ ｓｙｎｔｈｅｓｉｓ ａｎｄ Ｃａ（２＋）−ｓｔｉｍｕｌａｔｅｄ ｄｅｇｒａｄａｔｉｏｎ ｏｆ ｐｏｌｙｐｈｏｓｐｈｏｉｎｏｓｉｔｉｄｅｓ ｉｎ ｐａｎｃｒｅ", Ｂｉｏｃｈｅｍ Ｂｉｏｐｈｙｓ Ｒｅｓ Ｃｏｍｍｕｎ, 1996, Ｖｏｌ．２２８， Ｎｏ．２, ｐ．５７３−８ *

Also Published As

Publication number Publication date
WO2003064451A2 (en) 2003-08-07
WO2003064451A3 (en) 2003-09-04
EP1481093A4 (en) 2008-10-01
EP1481093A2 (en) 2004-12-01
US20060089320A1 (en) 2006-04-27
CA2473990A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
JP2006507795A (ja) 統合失調症の診断および治療のための標的、方法、ならびに試薬
JP2005535332A (ja) 結節性硬化症の診断法および治療法
US11274346B2 (en) Screening method
JP2006508642A (ja) 脂肪の蓄積を減少させる方法と、関連疾患を治療するための方法
JP2005516073A (ja) ＩＩβ型ホスホイノシチドリン酸キナーゼの調節
WO2006020755A2 (en) Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
US20140234321A1 (en) Hunk, a snf1-related kinase essential for mammary tumor metastasis
JP2005502368A (ja) アルツハイマー病および関連する神経変性障害のためのｆ−ボックス蛋白質の診断的および治療的使用
WO2001074298A2 (en) Methods and compositions for regulating memory consolidation
CA2858526A1 (en) Molecular targets for als and related disorders
US20100077493A1 (en) Genes and pathways involved in bipolar disorder
AU2003210794A1 (en) Modulation of type IIbeta phosphoinositide phosphate kinase
US7214374B2 (en) 12832, a novel human kinase-like molecule and uses thereof
JP2004524802A (ja) Ｐｈドメイン相互作用タンパク質
JP2005511660A (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
JP2005511660A6 (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
CN100467601C (zh) 作为ⅱ型糖尿病靶标的pim-3激酶
JP2005516626A (ja) Ｔｐｍｔのヒト遺伝子における多型ならびに診断的適用および治療的適用におけるその使用方法
US6660483B1 (en) Diagnostic marker for neurological conditions
US20060168667A1 (en) Minibrain homologous proteins involved in the regulation of energy homeostasis
US20060123502A1 (en) Assay methods for identifying RE2-like antagonists, methods of use, and non-human transgenic animals
US20050283842A1 (en) Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis
WO2003103704A2 (en) Proteins involved in the regulation of energy homeostasis
US20050272915A1 (en) Skrp, astray, string, vacm associated with metabolic control
US20180066318A1 (en) Methods of characterizing e-syt2 inhibitors, e-syt2 inhibitors, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090731

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100608